Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1116-1124

  Gavasso, S ^a,b   Gjertsen, B T ^a,b   Anderssen, E ^c   Myhr, K M ^a,b   Vedeler, C ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

immunogenicity; interferon beta; JAK STAT signalling; neutralizing antibodies; PBMC; phospho flow cytometry

Indexed keywords

JANUS KINASE; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84864143150     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511434066     Document Type: Article

References (39)

1. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008 ; 8: 970-976
2. Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci. 2008 ; 275: 7-17
3. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007 ; 28: 482-490
4. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002 ; 1: 457-462
5. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004 ; 251 (Suppl 2). II4 - I19
6. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010 ; 74 (Suppl 1). S17 - S24
7. Mitsdoerffer M, Kuchroo V. New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?. Ann Neurol. 2009 ; 65: 487-488
8. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007 ; 6: 975-990
9. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 ; 39: 285-294
10. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1996 ; 47: 889-894
11. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs. 2009 ; 23: 379-396
12. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology. 2004 ; 62: 719-725
13. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 ; 362: 1184-1191
14. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995 ; 45: 1277-1285
15. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 ; 352: 1498-1504
16. van der Voort LF, Kok A, Visser A, et al. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler. 2009 ; 15: 212-218
17. Sbardella E, Tomassini V, Gasperini C, et al. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol. 2009 ; 9: 54
18. Capra R, Sottini A, Cordioli C, et al. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol. 2007 ; 189: 102-110
19. Vallittu AM, Halminen M, Peltoniemi J, et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology. 2002 ; 58: 1786-1790
20. Sottini A, Capra R, Serana F, Chiarini M, Caimi L, Imberti L. Interferon-beta therapy monitoring in multiple sclerosis patients. Endocr Metab Immune Disord Drug Targets. 2009 ; 9: 14-28
21. Rani MR, Xu Y, Lee JC, et al. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci. 2009 ; 1182: 58-68
22. Goertsches RH, Hecker M, Koczan D, et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics. 2010 ; 11: 147-161
23. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
24. Gavasso S, Myhr KM, Vedeler C. Multiplexed phosphoprotein analysis in immune cells. Acta Neurol Scand Suppl. 2006 ; 183: 58-60
25. David M. Signal transduction by type I interferons. Biotechniques. 2002 ;: 58-65
26. Gavasso S. Flow cytometry and cell activation. Methods Mol Biol. 2009 ; 514: 35-46
27. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A. 2003 ; 55: 61-70
28. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res. 1980 ; 1: 61-70
29. Aarskog NK, Maroy T, Myhr KM, Vedeler CA. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol. 2009 ; 212: 148-150
30. Khan OA, Xia Q, Bever CT, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology. 1996 ; 46: 1639-1643
31. Khan OA, Dhib-Jalbut SS. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology. 1998 ; 51: 738-742
32. Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology. 2009 ; 73: 1493-1500
33. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008 ; 8: 923-934
34. van der Voort LF, Gilli F, Bertolotto A, et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol. 2010 ; 67: 402-407
35. Sominanda A, Lundkvist M, Fogdell-Hahn A, et al. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch Neurol. 2010 ; 67: 1095-1101
36. Malucchi S, Gilli F, Caldano M, et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol. 2010 ; 258: 895-903
37. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 57-62
38. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR. Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol. 2010 ; 185: 5888-5899
39. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 ; 129: 205-215